MX339608B - Anticuerpos del antigeno carcinoembrionario (cea). - Google Patents
Anticuerpos del antigeno carcinoembrionario (cea).Info
- Publication number
- MX339608B MX339608B MX2012002461A MX2012002461A MX339608B MX 339608 B MX339608 B MX 339608B MX 2012002461 A MX2012002461 A MX 2012002461A MX 2012002461 A MX2012002461 A MX 2012002461A MX 339608 B MX339608 B MX 339608B
- Authority
- MX
- Mexico
- Prior art keywords
- abms
- relates
- present
- monoclonal antibodies
- affinity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una molécula de unión a antígeno (ABM) que comprende una dominio humanizado de unión a antígeno de afinidad madurada, en comparación con el anticuerpo monoclonal de murino PRI1A3, en donde dicho dominio de unión a antígeno se une específicamente a antígeno carcinoembriónico humana (CEA) unido a membrana y se une al mismo epítope que, o es capaz de competir por la unión con, el anticuerpo monoclonal de murino PR1A3, y, en donde dicho dominio de unión a antígeno comprende una región variable de cadena pesada que comprende las regiones determinantes de complementariedad (CDRs): SEQ ID NO: 2, SEQ ID NO: 15 y SEQ ID NO: 25; y en donde dicho dominio de unión a antígeno comprende una región variable de cadena ligera que comprende las CDRs: SEQ ID NO: 45, SEQ ID NO:55, y SEQ ID NO: 56.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23850509P | 2009-08-31 | 2009-08-31 | |
| PCT/EP2010/062527 WO2011023787A1 (en) | 2009-08-31 | 2010-08-27 | Affinity-matured humanized anti cea monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012002461A MX2012002461A (es) | 2012-03-14 |
| MX339608B true MX339608B (es) | 2016-05-31 |
Family
ID=42985489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002461A MX339608B (es) | 2009-08-31 | 2010-08-27 | Anticuerpos del antigeno carcinoembrionario (cea). |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9068008B2 (es) |
| EP (1) | EP2473532B1 (es) |
| JP (1) | JP5744872B2 (es) |
| KR (1) | KR101528013B1 (es) |
| CN (1) | CN102741293B (es) |
| AR (1) | AR078111A1 (es) |
| AU (1) | AU2010288469A1 (es) |
| BR (1) | BR112012003983A2 (es) |
| CA (1) | CA2770174A1 (es) |
| CL (1) | CL2012000551A1 (es) |
| CO (1) | CO6491105A2 (es) |
| CR (1) | CR20120087A (es) |
| EC (1) | ECSP12011698A (es) |
| HK (1) | HK1176951A1 (es) |
| IL (1) | IL218038A0 (es) |
| MA (1) | MA33536B1 (es) |
| MX (1) | MX339608B (es) |
| PE (1) | PE20121552A1 (es) |
| RU (1) | RU2570554C2 (es) |
| SG (1) | SG178567A1 (es) |
| TW (1) | TW201121994A (es) |
| WO (1) | WO2011023787A1 (es) |
| ZA (1) | ZA201200954B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
| IL160170A0 (en) | 2001-08-03 | 2004-07-25 | Glycart Biotechnology Ag | A host cell engineered to produce a polypeptide having increased cytotoxicity |
| US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
| SI2673294T1 (sl) | 2011-02-10 | 2016-08-31 | Roche Glycart Ag | Mutirani polipeptidi interlevkina-2 |
| DK2681244T3 (da) * | 2011-03-02 | 2018-01-29 | Roche Glycart Ag | Cea-antistoffer |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| DK2748202T3 (en) | 2011-08-23 | 2018-09-17 | Roche Glycart Ag | BISPECIFIC ANTI-BINDING MOLECULES |
| MY169358A (en) | 2011-08-23 | 2019-03-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| GB201213858D0 (en) | 2012-08-03 | 2012-09-19 | Mab Design Ltd | Method |
| PL3434695T3 (pl) | 2012-08-07 | 2021-05-17 | Roche Glycart Ag | Ulepszona immunoterapia |
| KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
| CN104936985A (zh) * | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| RU2015140915A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| EP2961771B1 (en) | 2013-02-26 | 2020-01-01 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules specific to cd3 and cea |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| MD20160130A2 (ro) | 2014-04-27 | 2017-04-30 | Ccam Biotherapeutics Ltd. | Anticorpi umanizaţi contra CEACAM1 |
| MX2017001556A (es) | 2014-08-04 | 2017-05-15 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t. |
| EP3221355B1 (en) | 2014-11-20 | 2020-10-07 | F.Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| MA43025A (fr) | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 |
| KR20180085740A (ko) | 2015-12-09 | 2018-07-27 | 에프. 호프만-라 로슈 아게 | 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체 |
| IL259588B2 (en) | 2016-01-08 | 2023-09-01 | Hoffmann La Roche | Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3 |
| MX2018011542A (es) | 2016-03-22 | 2019-02-07 | Hoffmann La Roche | Moleculas biespecificas de celulas t activadas por proteasas. |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| EP3519437B1 (en) | 2016-09-30 | 2021-09-08 | F. Hoffmann-La Roche AG | Bispecific antibodies against p95her2 |
| PE20211116A1 (es) | 2018-02-08 | 2021-06-23 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso |
| CN113906053B (zh) * | 2019-06-26 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 抗cea抗体及其应用 |
| BR112021026293A2 (pt) | 2019-06-26 | 2022-03-03 | Hoffmann La Roche | Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula |
| CN110713539B (zh) * | 2019-09-23 | 2021-04-16 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| CN110862456B (zh) * | 2019-09-23 | 2021-04-09 | 华道(上海)生物医药有限公司 | 一种抗癌胚抗原的抗体及其制备方法和用途 |
| MX2022016069A (es) | 2020-06-19 | 2023-02-02 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y cd19. |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| WO2023147426A2 (en) * | 2022-01-27 | 2023-08-03 | Janssen Biotech, Inc. | Enhanced protein compositions |
| WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| JP3358141B2 (ja) * | 1992-05-07 | 2002-12-16 | アメルシャム ヘルス アクスイェ セルスカプ | 錯化剤と金属放射性核種イオンとの錯体及びそれを含む診断用組成物 |
| GB9317423D0 (en) * | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2568898T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| EP1305437B1 (en) | 2000-07-31 | 2010-09-01 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6815175B2 (en) * | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| IL160170A0 (en) | 2001-08-03 | 2004-07-25 | Glycart Biotechnology Ag | A host cell engineered to produce a polypeptide having increased cytotoxicity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US8932825B2 (en) | 2001-12-27 | 2015-01-13 | Glycofi Inc. | Method to engineer mammalian-type carbohydrate structures |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003219402B2 (en) | 2002-03-19 | 2008-05-08 | Stichting Dienst Landbouwkundig Onderzoek | GnTIII (UDP-n-acethylglucosamine:beta-D mannoside beta (1,4)-N-acethylglucosaminy ltransferase III) expression in plants |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| ES2362419T3 (es) | 2002-04-09 | 2011-07-05 | Kyowa Hakko Kirin Co., Ltd. | Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa. |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| AU2003248982B2 (en) * | 2002-08-01 | 2009-12-10 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| PT1539966E (pt) | 2002-09-12 | 2010-09-14 | Greenovation Biotech Gmbh | Método de produção de proteínas |
| WO2004057002A2 (en) | 2002-12-20 | 2004-07-08 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| SG179292A1 (en) | 2003-01-22 | 2012-04-27 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| EP2357237A1 (en) * | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| DK2681244T3 (da) * | 2011-03-02 | 2018-01-29 | Roche Glycart Ag | Cea-antistoffer |
-
2010
- 2010-08-27 AU AU2010288469A patent/AU2010288469A1/en not_active Abandoned
- 2010-08-27 CN CN201080048622.1A patent/CN102741293B/zh not_active Expired - Fee Related
- 2010-08-27 WO PCT/EP2010/062527 patent/WO2011023787A1/en active Application Filing
- 2010-08-27 KR KR1020127008265A patent/KR101528013B1/ko active IP Right Grant
- 2010-08-27 BR BR112012003983-0A patent/BR112012003983A2/pt not_active Application Discontinuation
- 2010-08-27 CA CA2770174A patent/CA2770174A1/en not_active Abandoned
- 2010-08-27 EP EP10745651.9A patent/EP2473532B1/en active Active
- 2010-08-27 SG SG2012013306A patent/SG178567A1/en unknown
- 2010-08-27 MX MX2012002461A patent/MX339608B/es active IP Right Grant
- 2010-08-27 RU RU2012112340/10A patent/RU2570554C2/ru active
- 2010-08-27 PE PE2012000266A patent/PE20121552A1/es not_active Application Discontinuation
- 2010-08-27 JP JP2012526072A patent/JP5744872B2/ja not_active Expired - Fee Related
- 2010-08-30 AR ARP100103166A patent/AR078111A1/es not_active Application Discontinuation
- 2010-08-30 TW TW099129130A patent/TW201121994A/zh unknown
- 2010-08-31 US US12/872,908 patent/US9068008B2/en active Active
-
2012
- 2012-01-30 CO CO12014021A patent/CO6491105A2/es not_active Application Discontinuation
- 2012-02-08 ZA ZA2012/00954A patent/ZA201200954B/en unknown
- 2012-02-09 IL IL218038A patent/IL218038A0/en unknown
- 2012-02-20 CR CR20120087A patent/CR20120087A/es unknown
- 2012-02-27 MA MA34650A patent/MA33536B1/fr unknown
- 2012-02-28 EC ECSP12011698 patent/ECSP12011698A/es unknown
- 2012-02-29 CL CL2012000551A patent/CL2012000551A1/es unknown
-
2013
- 2013-04-15 HK HK13104510.8A patent/HK1176951A1/xx not_active IP Right Cessation
-
2015
- 2015-05-26 US US14/721,795 patent/US20160075795A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MA33536B1 (fr) | 2012-08-01 |
| AR078111A1 (es) | 2011-10-12 |
| AU2010288469A1 (en) | 2012-03-01 |
| PE20121552A1 (es) | 2012-11-26 |
| US9068008B2 (en) | 2015-06-30 |
| KR101528013B1 (ko) | 2015-06-16 |
| CL2012000551A1 (es) | 2012-10-12 |
| US20110104148A1 (en) | 2011-05-05 |
| CA2770174A1 (en) | 2011-03-03 |
| BR112012003983A2 (pt) | 2021-09-14 |
| EP2473532A1 (en) | 2012-07-11 |
| CN102741293A (zh) | 2012-10-17 |
| IL218038A0 (en) | 2012-04-30 |
| CN102741293B (zh) | 2015-04-01 |
| SG178567A1 (en) | 2012-04-27 |
| RU2570554C2 (ru) | 2015-12-10 |
| EP2473532B1 (en) | 2017-06-21 |
| KR20120060874A (ko) | 2012-06-12 |
| HK1176951A1 (en) | 2013-08-09 |
| ECSP12011698A (es) | 2012-03-30 |
| WO2011023787A1 (en) | 2011-03-03 |
| ZA201200954B (en) | 2014-07-30 |
| US20160075795A1 (en) | 2016-03-17 |
| JP5744872B2 (ja) | 2015-07-08 |
| TW201121994A (en) | 2011-07-01 |
| RU2012112340A (ru) | 2013-10-10 |
| JP2013502913A (ja) | 2013-01-31 |
| CO6491105A2 (es) | 2012-07-31 |
| CR20120087A (es) | 2012-03-22 |
| MX2012002461A (es) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG178567A1 (en) | Affinity-matured humanized anti cea monoclonal antibodies | |
| PH12012502376A1 (en) | Modified antigen binding molecules with altered cell signaling activity | |
| TW200720439A (en) | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function | |
| TW200639181A (en) | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
| WO2008017963A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
| ECSP21023271A (es) | Anticuerpos cd20 con función del efector y afinidad de enlace al receptor fc mejoradas | |
| CR8389A (es) | Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |